- Home
- LNT vs RPRX Comparison
LNT vs RPRX Comparison
Compare LNT & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNT
- RPRX
- Stock Information
- Founded
- LNT 1917
- RPRX 1996
- Country
- LNT United States
- RPRX United States
- Employees
- LNT N/A
- RPRX N/A
- Industry
- LNT Power Generation
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- LNT Utilities
- RPRX Health Care
- Exchange
- LNT Nasdaq
- RPRX Nasdaq
- Market Cap
- LNT 15.9B
- RPRX 14.3B
- IPO Year
- LNT N/A
- RPRX 2020
- Fundamental
- Price
- LNT $62.23
- RPRX $32.88
- Analyst Decision
- LNT Buy
- RPRX Strong Buy
- Analyst Count
- LNT 8
- RPRX 4
- Target Price
- LNT $63.56
- RPRX $42.50
- AVG Volume (30 Days)
- LNT 2.5M
- RPRX 5.8M
- Earning Date
- LNT 05-08-2025
- RPRX 05-08-2025
- Dividend Yield
- LNT 3.26%
- RPRX 2.68%
- EPS Growth
- LNT 5.63
- RPRX 37.60
- EPS
- LNT 2.90
- RPRX 2.45
- Revenue
- LNT $4,078,000,000.00
- RPRX $2,263,845,000.00
- Revenue This Year
- LNT $9.27
- RPRX $31.16
- Revenue Next Year
- LNT $4.85
- RPRX $6.37
- P/E Ratio
- LNT $21.46
- RPRX $13.41
- Revenue Growth
- LNT 2.44
- RPRX 1.13
- 52 Week Low
- LNT $49.25
- RPRX $24.05
- 52 Week High
- LNT $66.54
- RPRX $34.32
- Technical
- Relative Strength Index (RSI)
- LNT 53.39
- RPRX 51.49
- Support Level
- LNT $61.05
- RPRX $32.15
- Resistance Level
- LNT $62.48
- RPRX $32.82
- Average True Range (ATR)
- LNT 1.14
- RPRX 0.72
- MACD
- LNT 0.06
- RPRX -0.07
- Stochastic Oscillator
- LNT 65.52
- RPRX 33.72
About LNT Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electric customers and 425,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.